Increased hemostasis potential persists in women with previous thromboembolism with or without APC resistance

被引:21
作者
Antovic, A
Blombäck, M
Bremme, K
Van Rooijen, M
He, S
机构
[1] Karolinska Hosp, Clin Chem, S-17176 Stockholm, Sweden
[2] Karolinska Hosp, Karolinska Inst, Dept Woman & Child Hlth, S-17176 Stockholm, Sweden
[3] Karolinska Hosp, Karolinska Inst, Coagulat Res Dept Surg Sci, S-17176 Stockholm, Sweden
关键词
APC resistance; DVT recurrence; factor V Leiden mutation; overall hemostasis potential;
D O I
10.1111/j.1538-7836.2003.00451.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Activated thrombin generation and depressed fibrinolysis due to the presence of activated protein C (APC) resistance with or without factor (F)V Leiden mutation are associated with development of deep venous thrombosis (DVT). Objective: A better understanding of the mechanism behind the risk of recurrence of DVT, using our new, recently developed assay of overall hemostasis potential (OHP). Patients and methods: Levels of OHP, as well as APC resistance and FV Leiden mutation, were determined in 88 women (cases) who had previously experienced DVT in connection with pregnancy, and in 25 young healthy individuals (controls). Clotting time and clot lysis time were also investigated. Results: OHP levels in the patients were increased compared with the controls. In the cases with APC resistance and the Leiden mutation this imbalance in hemostasis potential was more severe than in those without. The group with the more severe imbalance had shorter clotting times and longer clot lysis times. Conclusions: A procoagulant state perseveres in patients with a history of pregnancy-related DVT, even after the symptomatic phase is over. The mechanisms behind such an imbalance in overall hemostasis are enhanced thrombin generation and depressed fibrinolysis. These findings may underscore the need for thromboprophylaxis to prevent recurrence of thromboembolism in risk situations.
引用
收藏
页码:2531 / 2535
页数:5
相关论文
共 23 条
[1]   The assay of overall haemostasis potential used to monitor the low molecular mass (weight) heparin, dalteparin, treatment in pregnant women with previous thromboembolism [J].
Antovic, A ;
Blombäck, M ;
Bremme, K ;
He, S .
BLOOD COAGULATION & FIBRINOLYSIS, 2002, 13 (03) :181-186
[2]   Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation [J].
Antovic, JP ;
Blombäck, M .
THROMBOSIS RESEARCH, 2002, 106 (01) :59-62
[3]   An antifibrinolytic mechanism describing the prothrombotic effect associated with factor V-Leiden [J].
Bajzar, L ;
Kalafatis, M ;
Simioni, P ;
Tracy, PB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (38) :22949-22952
[4]   The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent [J].
Bajzar, L ;
Nesheim, ME ;
Tracy, PB .
BLOOD, 1996, 88 (06) :2093-2100
[5]   MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C [J].
BERTINA, RM ;
KOELEMAN, BPC ;
KOSTER, T ;
ROSENDAAL, FR ;
DIRVEN, RJ ;
DERONDE, H ;
VANDERVELDEN, PA ;
REITSMA, PH .
NATURE, 1994, 369 (6475) :64-67
[6]   FIBRIN GEL STRUCTURE AND CLOTTING TIME [J].
BLOMBACK, B ;
OKADA, M .
THROMBOSIS RESEARCH, 1982, 25 (1-2) :51-70
[7]   FIBRIN IN HUMAN PLASMA - GEL ARCHITECTURES GOVERNED BY RATE AND NATURE OF FIBRINOGEN ACTIVATION [J].
BLOMBACK, B ;
CARLSSON, K ;
FATAH, K ;
HESSEL, B ;
PROCYK, R .
THROMBOSIS RESEARCH, 1994, 75 (05) :521-538
[8]   PHOSPHOLIPID ANTIBODIES AND RESISTANCE TO ACTIVATED PROTEIN-C IN WOMEN WITH THROMBOPHILIA [J].
BOKAREWA, MI ;
BLOMBACK, M ;
BREMME, K .
BLOOD COAGULATION & FIBRINOLYSIS, 1995, 6 (05) :417-422
[9]   Acquired activated protein-C resistance in pregnancy and association with increased thrombin generation and fetal weight [J].
Clark, P ;
Walker, ID ;
Greer, I .
LANCET, 1999, 353 (9149) :292-293
[10]   DEVELOPMENT OF RESISTANCE TO ACTIVATED PROTEIN-C DURING PREGNANCY [J].
CUMMING, AM ;
TAIT, RC ;
FILDES, S ;
YOONG, A ;
KEENEY, S ;
HAY, CRM .
BRITISH JOURNAL OF HAEMATOLOGY, 1995, 90 (03) :725-727